Literature DB >> 23658323

The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence.

Ichiyo Shibahara1, Yukihiko Sonoda, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Toshihiro Kumabe, Mika Watanabe, Hiroyoshi Suzuki, Takashi Watanabe, Chikashi Ishioka, Teiji Tominaga.   

Abstract

BACKGROUND: Glioblastoma carries a poor prognosis primarily because of its high rate of recurrence. The ability to predict the recurrence pattern and timing would be highly useful for determining effective treatment strategies. We examined the correlation between prognostic factors and the pattern of recurrence in patients with primary glioblastoma. In particular, we examined whether there was a correlation between the expression of CD133 and glioblastoma recurrence.
METHODS: We retrospectively analyzed 112 patients with primary glioblastoma. The timing and pattern (local or distant) of the initial recurrence were obtained from medical records. To identify factors predictive of recurrence, we examined CD133 expression by Western blots and immunohistochemistry, clinical (age, sex, KPS, Ki67 labeling index, surgery, ventricular entry) and genetic (IDH1, 7p, 9p, 10q, MGMT) factors.
RESULTS: Of the 112 patients, 99 suffered recurrence. The first recurrence was local in 77 patients and distant in 22 patients. Among the factors to predict the pattern of recurrence, CD133 expression was significantly higher in distant than in local recurrence. Of the factors to predict the timing of recurrence, high CD133 expression was associated with shorter time to distant recurrence in both univariate and multivariate analyses (P = .0011 and P = .038, respectively).
CONCLUSIONS: The expression of CD133 may be a predictor of the pattern and timing of recurrence of primary glioblastoma.

Entities:  

Keywords:  CD133; distant recurrence; glioblastoma; local recurrence; stem cells

Mesh:

Substances:

Year:  2013        PMID: 23658323      PMCID: PMC3748916          DOI: 10.1093/neuonc/not066

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  41 in total

1.  PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

Authors:  J S Smith; I Tachibana; S M Passe; B K Huntley; T J Borell; N Iturria; J R O'Fallon; P L Schaefer; B W Scheithauer; C D James; J C Buckner; R B Jenkins
Journal:  J Natl Cancer Inst       Date:  2001-08-15       Impact factor: 13.506

2.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

3.  Ventricular entry during resection of malignant gliomas: effect on intracranial cerebrospinal fluid tumor dissemination.

Authors:  J P Elliott; G E Keles; M Waite; N Temkin; M S Berger
Journal:  J Neurosurg       Date:  1994-05       Impact factor: 5.115

4.  Genetic pathways to glioblastoma: a population-based study.

Authors:  Hiroko Ohgaki; Pierre Dessen; Benjamin Jourde; Sonja Horstmann; Tomofumi Nishikawa; Pier-Luigi Di Patre; Christoph Burkhard; Danielle Schüler; Nicole M Probst-Hensch; Paulo César Maiorka; Nathalie Baeza; Paola Pisani; Yasuhiro Yonekawa; M Gazi Yasargil; Urs M Lütolf; Paul Kleihues
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

5.  Intractable vomiting as an early clinical symptom of cerebrospinal fluid seeding to the fourth ventricle in patients with high-grade astrocytoma.

Authors:  Miki Fujimura; Toshihiro Kumabe; Hidefumi Jokura; Reizo Shirane; Takashi Yoshimoto; Teiji Tominaga
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

6.  PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma.

Authors:  Hideaki Kato; Miki Fujimura; Toshihiro Kumabe; Chikashi Ishioka; Ryunosuke Kanamaru; Takashi Yoshimoto
Journal:  J Clin Neurosci       Date:  2004-01       Impact factor: 1.961

7.  Cancerous stem cells can arise from pediatric brain tumors.

Authors:  Houman D Hemmati; Ichiro Nakano; Jorge A Lazareff; Michael Masterman-Smith; Daniel H Geschwind; Marianne Bronner-Fraser; Harley I Kornblum
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-26       Impact factor: 11.205

8.  Identification of a cancer stem cell in human brain tumors.

Authors:  Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

9.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.

Authors:  Ichiyo Shibahara; Yukihiko Sonoda; Masayuki Kanamori; Ryuta Saito; Yoji Yamashita; Toshihiro Kumabe; Mika Watanabe; Hiroyoshi Suzuki; Shunsuke Kato; Chikashi Ishioka; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2011-10-06       Impact factor: 3.850

View more
  29 in total

1.  Malignant clinical features of anaplastic gliomas without IDH mutation.

Authors:  Ichiyo Shibahara; Yukihiko Sonoda; Takuhiro Shoji; Masayuki Kanamori; Ryuta Saito; Tomoo Inoue; Tomohiro Kawaguchi; Yoji Yamashita; Takashi Watanabe; Toshihiro Kumabe; Mika Watanabe; Hiroyoshi Suzuki; Teiji Tominaga
Journal:  Neuro Oncol       Date:  2014-06-23       Impact factor: 12.300

2.  Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.

Authors:  Mingzhi Han; Laixiu Guo; Ya Zhang; Bin Huang; Anjing Chen; Weiliang Chen; Xupeng Liu; Shicheng Sun; Kun Wang; Ao Liu; Xingang Li
Journal:  Mol Neurobiol       Date:  2015-01-15       Impact factor: 5.590

3.  Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study.

Authors:  Yukihiko Sonoda; Ichiyo Shibahara; Ken-Ichiro Matsuda; Ryuta Saito; Tomoyuki Kawataki; Masaya Oda; Yuichi Sato; Hirokazu Sadahiro; Sadahiro Nomura; Toshio Sasajima; Takaaki Beppu; Masayuki Kanamori; Kaori Sakurada; Toshihiro Kumabe; Teiji Tominaga; Hiroyuki Kinouchi; Hiroaki Shimizu; Kuniaki Ogasawara; Michiyasu Suzuki
Journal:  J Neurooncol       Date:  2017-05-22       Impact factor: 4.130

4.  High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma.

Authors:  Wei Zhang; Huanran Chen; Shengqing Lv; Hui Yang
Journal:  Mol Neurobiol       Date:  2015-05-17       Impact factor: 5.590

5.  Prognostic implication of NOTCH1 in early stage oral squamous cell cancer with occult metastases.

Authors:  Shan Wang; Haixia Fan; Jiankai Xu; Eryang Zhao
Journal:  Clin Oral Investig       Date:  2017-09-02       Impact factor: 3.573

6.  Prognostic significance of CD147 in patients with glioblastoma.

Authors:  Min Yang; Yang Yuan; Hua Zhang; Ming Yan; Shumei Wang; Fuqiang Feng; Peigang Ji; Yi Li; Baofu Li; Guodong Gao; Jipei Zhao; Liang Wang
Journal:  J Neurooncol       Date:  2013-08-08       Impact factor: 4.130

7.  CPEB4 interacts with Vimentin and involves in progressive features and poor prognosis of patients with astrocytic tumors.

Authors:  Wei Chen; Zhen Hu; Xi-Zhao Li; Jun-Liang Li; Xin-Ke Xu; Hai-Gang Li; Yeqing Liu; Bai-Hui Liu; Wei-Hua Jia; Fang-Cheng Li
Journal:  Tumour Biol       Date:  2015-11-06

8.  Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.

Authors:  Jianfei Ji; Valeria A Judkowski; Gentao Liu; Hongqiang Wang; Alcinette Bunying; Zhenhua Li; Minlin Xu; James Bender; Clemencia Pinilla; John S Yu
Journal:  Stem Cells Transl Med       Date:  2013-12-27       Impact factor: 6.940

9.  Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas.

Authors:  Tingfen Huang; Shufa Li; Zhen Yang; Jicheng Liu; Yunwei Han
Journal:  Mol Neurobiol       Date:  2015-11-19       Impact factor: 5.590

10.  Neuroimaging classification of progression patterns in glioblastoma: a systematic review.

Authors:  Rory J Piper; Keerthi K Senthil; Jiun-Lin Yan; Stephen J Price
Journal:  J Neurooncol       Date:  2018-03-30       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.